Calcimimetics as allosteric modulator of CaSR is currently being tested for the treatment of primary hyperparathyroidism, and CaSR-based therapeutics will likely be applicable to other disorders in which CaSRs are under- or overactive58. The gene discussed is CASR; the disease is primary hyperparathyroidism.